Your browser doesn't support javascript.
loading
The influencing factors of renal response in newly diagnosed multiple myeloma patients with renal impairment / 中华血液学杂志
Chinese Journal of Hematology ; (12): 141-147, 2023.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-969690
Responsible library: WPRO
ABSTRACT

Objective:

To investigate the causative factors of renal function in newly diagnosed multiple myeloma (MM) patients with renal inadequacy.

Methods:

181 MM patients with renal impairment from August 2007 to October 2021 at Peking Union Medical College Hospital were recruited, whose baseline chronic kidney disease (CKD) stage was 3-5. Statistical analysis was performed based on laboratory tests, treatment regimens, hematological responses, and survival among various renal function efficacy groups. A logistic regression model was employed in multivariate analysis.

Results:

A total of 181 patients were recruited, and 277 patients with CKD stages 1-2 were chosen as controls. The majority choose the BCD and VRD regimens. The progression-free survival (PFS) (14.0 months vs 24.8 months, P<0.001) and overall survival (OS) (49.2 months vs 79.7 months, P<0.001) of patients with renal impairment was considerably shorter. Hypercalcemia (P=0.013, OR=5.654) , 1q21 amplification (P=0.018, OR=2.876) , and hematological response over a partial response (P=0.001, OR=4.999) were independent predictive factors for renal function response. After treatment, those with improvement in renal function had a longer PFS than those without (15.6 months vs 10.2 months, P=0.074) , but there was no disparity in OS (56.5 months vs 47.3 months, P=0.665) .

Conclusion:

Hypercalcemia, 1q21 amplification, and hematologic response were independent predictors of the response of renal function in NDMM patients with renal impairment. MM patients with CKD 3-5 at baseline still have worse survival. Improvement in renal function after treatment is attributed to the improvement in PFS.
Subject(s)

Full text: Available Database: WPRIM (Western Pacific) Main subject: Prognosis / Antineoplastic Combined Chemotherapy Protocols / Retrospective Studies / Chromosome Aberrations / Renal Insufficiency, Chronic / Bortezomib / Hypercalcemia / Kidney / Multiple Myeloma Limits: Humans Language: Chinese Journal: Chinese Journal of Hematology Year: 2023 Document type: Article
Full text: Available Database: WPRIM (Western Pacific) Main subject: Prognosis / Antineoplastic Combined Chemotherapy Protocols / Retrospective Studies / Chromosome Aberrations / Renal Insufficiency, Chronic / Bortezomib / Hypercalcemia / Kidney / Multiple Myeloma Limits: Humans Language: Chinese Journal: Chinese Journal of Hematology Year: 2023 Document type: Article
...